Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  KOREA EXCHANGE (KOSDAQ)  >  Celltrion, Inc.    068270   KR7068270008

CELLTRION, INC. (068270)
My previous session
Most popular
  Report  
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (KRW)
Sales 2018 1 151 B
EBIT 2018 568 B
Net income 2018 436 B
Finance 2018 135 B
Yield 2018 -
Sales 2019 1 478 B
EBIT 2019 762 B
Net income 2019 587 B
Finance 2019 354 B
Yield 2019 -
P/E ratio 2018 76,02
P/E ratio 2019 56,94
EV / Sales2018 28,5x
EV / Sales2019 22,1x
Capitalization 32 979 B
More Financials
Company
Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals.It operates through the Biopharmaceuticals, Chemical Drugs and Others businesses.Its products include remsima and biosimilars.The company was founded on February 27, 1991 and is headquartered in Incheon,... 
More about the company
Surperformance© ratings of Celltrion, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on CELLTRION, INC.
08/16CELLTRION : Enters into Phases 1 and 3 Clinical Trials for the Adalimumab Biosim..
AQ
08/10CELLTRION : Begins Global Phase 3 Clinical Trial for Its Bevacizumab Biosimilar ..
BU
08/09CELLTRION : Announces Simultaneous Phase 1, Phase 3 Trials for Adalimumab Biosim..
AQ
08/09CELLTRION : hit with Form 483 over troublesome Incheon plant
AQ
08/08CELLTRION : Enters into Phases 1 and 3 Clinical Trials for the Adalimumab Biosim..
AQ
08/07CELLTRION : Enters into Phases 1 and 3 Clinical Trials for the Adalimumab Biosim..
BU
08/02Celltrion wins another biosimilar infliximab lawsuit
AQ
07/26Upbeat Roche bests rival Novartis as new drugs fuel growth
RE
06/18CELLTRION : Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar
BU
06/14CELLTRION : Launches Bio CDMO Business for the Development of New Drugs
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
08/16REGENERON PHARMACEUTICALS : Teva Report Positive Phase 3 Fasinumab Results
DJ
08/03Roche Drug for Brain Disease Granted European Fast-Track
DJ
08/02Regeneron Closes Up 7% After 2Q Earnings Beat -- Data Talk
DJ
08/02REGENERON PHARMACEUTICALS : Beats Earnings Estimates
DJ
07/31UNITED THERAPEUTICS : Medtronic Get FDA OK for Remodulin Implantable System
DJ
More sector news : Biotechnology & Medical Research - NEC
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 278 999  KRW
Spread / Average Target 6,1%
EPS Revisions
Managers
NameTitle
Wu-Sung Ki Co-Chief Executive Officer & Director
Hyung-Ki Kim Co-Chief Executive Officer & Director
Jung-Jin Seo Director
Dong-Il Kim Outside Director
Joseph Lee Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.29 483
CELLTRION, INC.--.--%29 483
IQVIA HOLDINGS INC22.86%24 367
LONZA GROUP17.93%23 220
INCYTE CORPORATION-27.36%14 625
SEATTLE GENETICS, INC.39.51%11 852